A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma SA. Completed at 10 sites in 4 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.
Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.
Among the 34 studies testing brivaracetam in Epilepsy, this one is the 26th largest by enrollment, is one of 2 that started in 2012, is one of 21 in phase 3, and was the 20th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Belgium, Czechia and 8 more countries
Ages 1 mo+
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2012.
This study's enrollment of 26 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 34 interventional studies. Of the 31 that completed or were terminated, 23 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma SA, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma SA is the lead sponsor of 28 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 92nd largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2012, is one of 74 in phase 3, and was the 86th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing brivaracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource use for BRV (for subjects entering N01372 from a study where pharmacoeconomic data was collected). BRV will be used at doses up to maximum of 200 mg/day, as adjunctive treatment in subjects aged 16 years or older with Epilepsy.
Flexible dosing up to 200 mg/day, twice daily (10, 25 and 50 mg oral film-coated tablets). The study will continue until either regulatory approval of BRV has been granted by any Health Authority in an indication of adjunctive treatment of Epilepsy, or until the Sponsor decides to close the study, or until the BRV development is stopped by the Sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
Drug: Brivaracetam
Flexible dosing, can up and down-titrate as needed.
Also known as: UCB34714
Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period
TEAEs were defined as AEs that had onset on or after the day of first study medication dose. An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.
Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Percentage of Subjects Withdrawn Due to an Adverse Event (AE) During the Evaluation Period
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects withdrawn due to an AE.
Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Occurrence of a Serious Adverse Event (SAE) During the Evaluation Period
SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defects. Results are presented as the percentage of subjects with at least one SAE during this study.
Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Frequency of Partial-Onset Seizure (POS) Type I Per 28 Days During the Evaluation Period for Subjects With Focal-onset Epilepsy
The POS frequency is standardized to a 28-day duration. Results are presented as the median number of seizures per 28 days.
Time frame: From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)
Percentage of Change in Partial-Onset-Seizure (POS) Type I Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected
The POS frequency is standardized to a 28-day duration. Results are presented as the median percentage of reduction per 28 days. Negative values indicate improvement from Baseline.
Time frame: From Baseline of the previous study to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 49 months)
50 % Responder Rate in Partial-Onset-Seizure (POS) Type I Frequency From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected
The POS frequency is standardized to a 28-day duration. A responder is defined as a subject with a \>=50% reduction in seizure frequency from the Baseline Period of the previous study. Results are presented as the percentage of subjects with 50 % responder rate in POS Type I frequency.
Time frame: From Baseline of the previous study to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 49 months)
This study started to enroll subjects in October 2012 and concluded in August 2016.
| Milestone | Brivaracetam Focal Epilepsy | Brivaracetam Generalized Epilepsy |
|---|---|---|
| Started | 19 | 7 |
| Completed | 11 | 2 |
| Not completed | 8 | 5 |
| Withdrew: Lack of efficacy | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Subject choice | 2 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Patient moving | 1 | 0 |
| Withdrew: Non compliance | 1 | 0 |
TEAEs were defined as AEs that had onset on or after the day of first study medication dose. An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.
| percentage of subjects | Brivaracetam Focal Epilepsy (SS) | Brivaracetam Generalized Epilepsy (SS) |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period | 78.9 | 71.4 |
An AE was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. Results are presented as the percentage of subjects withdrawn due to an AE.
| percentage of subjects | Brivaracetam Focal Epilepsy (SS) | Brivaracetam Generalized Epilepsy (SS) |
|---|---|---|
| Percentage of Subjects Withdrawn Due to an Adverse Event (AE) During the Evaluation Period | 0 | 14.3 |
SAEs include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity or are a congenital anomaly/birth defects. Results are presented as the percentage of subjects with at least one SAE during this study.
| percentage of subjects | Brivaracetam Focal Epilepsy (SS) | Brivaracetam Generalized Epilepsy (SS) |
|---|---|---|
| Occurrence of a Serious Adverse Event (SAE) During the Evaluation Period | 26.3 | 28.6 |
The POS frequency is standardized to a 28-day duration. Results are presented as the median number of seizures per 28 days.
| Seizures per 28 days | Brivaracetam Focal Epilepsy (EAS) |
|---|---|
| Frequency of Partial-Onset Seizure (POS) Type I Per 28 Days During the Evaluation Period for Subjects With Focal-onset Epilepsy | 0.4 (0 to 124) |
The POS frequency is standardized to a 28-day duration. Results are presented as the median percentage of reduction per 28 days. Negative values indicate improvement from Baseline.
| percentage of change | Brivaracetam Focal Epilepsy (EAS) |
|---|---|
| Percentage of Change in Partial-Onset-Seizure (POS) Type I Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected | -56.3 (-97 to 717) |
The POS frequency is standardized to a 28-day duration. A responder is defined as a subject with a \>=50% reduction in seizure frequency from the Baseline Period of the previous study. Results are presented as the percentage of subjects with 50 % responder rate in POS Type I frequency.
| percentage of subjects | Brivaracetam Focal Epilepsy (EAS) |
|---|---|
| 50 % Responder Rate in Partial-Onset-Seizure (POS) Type I Frequency From Baseline of the Previous Study to the Evaluation Period for Subjects With Focal-onset Epilepsy Entering N01372 From a Study Where Baseline Seizure Data Was Collected | 54.5 |
Collected over Adverse events collection started at Day 0 and continued up to 30 days after last intake of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brivaracetam Focal Epilepsy (SS) | — | 5/19 (26.3%) | 13/19 (68.4%) |
| Brivaracetam Generalized Epilepsy (SS) | — | 2/7 (28.6%) | 5/7 (71.4%) |
| Event | Brivaracetam Focal Epilepsy (SS) | Brivaracetam Generalized Epilepsy (SS) |
|---|---|---|
| Cardio-respiratory arrestCardiac disorders | 0/19 | 1/7 |
| DrowningGeneral disorders | 0/19 | 1/7 |
| Status epilepticusNervous system disorders | 1/19 | 1/7 |
| ConvulsionNervous system disorders | 2/19 | 0/7 |
| LeukocytosisBlood and lymphatic system disorders | 1/19 | 0/7 |
| Myocardial infarctionCardiac disorders | 1/19 | 0/7 |
| Chest painGeneral disorders | 1/19 | 0/7 |
| PneumoniaInfections and infestations | 1/19 | 0/7 |
| SepsisInfections and infestations | 1/19 | 0/7 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/19 | 0/7 |
| Event | Brivaracetam Focal Epilepsy (SS) | Brivaracetam Generalized Epilepsy (SS) |
|---|---|---|
| HeadacheNervous system disorders | 7/19 | 1/7 |
| Urinary tract infectionInfections and infestations | 2/19 | 2/7 |
| Upper respiratory tractInfections and infestations | 1/19 | 2/7 |
| FatigueGeneral disorders | 3/19 | 0/7 |
| Back painMusculoskeletal and connective tissue disorders | 3/19 | 1/7 |
| ConvulsionNervous system disorders | 3/19 | 0/7 |
| DizzinessNervous system disorders | 3/19 | 0/7 |
| NauseaGastrointestinal disorders | 2/19 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 1/19 | 1/7 |
| VomitingGastrointestinal disorders | 1/19 | 1/7 |
Baseline Characteristics refer to the Safety Set, which consisted of all subjects who received at least 1 dose of study medication.
| Age, Categorical(Participants) | Brivaracetam Focal Epilepsy | Brivaracetam Generalized Epilepsy | Total Title |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 7 | 26 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Brivaracetam Focal Epilepsy | Brivaracetam Generalized Epilepsy | Total Title |
|---|---|---|---|
| Arithmetic mean (standard deviation) | 38.6 ± 10.9 | 30.7 ± 13.2 | 36.5 ± 11.9 |
| Sex: Female, Male(Participants) | Brivaracetam Focal Epilepsy | Brivaracetam Generalized Epilepsy | Total Title |
|---|---|---|---|
| Female | 7 | 5 | 12 |
| Male | 12 | 2 | 14 |
The record gives a start of Oct 2012, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brivaracetam